bioAffinity Technologies (BIAF) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on bioAffinity Technologies (BIAF) is Strong Underperform.

The composite score behind that read is -0.69, weighing +0.09 of bullish evidence against -0.63 bearish.

bioAffinity Technologies last closed at $2.96, +4.59% on the session.

Against the IVW growth benchmark the position is +3.65% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

32 graded predictions for BIAF so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks bioAffinity Technologies in the 4th percentile on return on equity, where 100 is best.

bioAffinity Technologies is classified under Health Care / Biotechnology, with a market capitalisation of $3.63M.

StockMap tracks bioAffinity Technologies as the 379th largest of the 390 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 127 Neutral, 56 Strong Underperform and 7 Moderate Outperform.

On that composite bioAffinity Technologies ranks 379th of 390 in the group, against a group median of -0.27.